Avacta publishes 2025 annual report

AMERICAN VIRTUAL CLOUD TECHNOLOGIES, INC

AMERICAN VIRTUAL CLOUD TECHNOLOGIES, INC

AVCT

0.00
  • Avacta annual report for the year ended Dec. 31, 2025, highlighted its shift to a pure-play oncology therapeutics group.
  • Completed the diagnostics exit with the sale of Launch Diagnostics in March 2025 for GBP 12.9 million and Coris BioConcept in August 2025 for GBP 2.15 million.
  • AVA6000 Phase 1b expansion continued, supported by efficacy signals in salivary gland cancer and regulator agreement to lift the lifetime doxorubicin dose cap.
  • AVA6103 moved into the clinic, with an FDA IND filed in late Q4 2025 and first patient treated in March 2026 in the FOCUS-01 Phase 1 trial.
  • Funding activity included GBP 22.5 million equity raised in 2025, followed by an oversubscribed GBP 10 million placing in March 2026, extending runway into Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avacta Group plc published the original content used to generate this news brief on May 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.